Supriya Lifescience’s Initial Public Offering (IPO) was registered 2.33 times on Thursday, the first day of issuance.
The public issue is registered 11.84 times in the retail portfolio and 0.66 times in the non-institutional investor portfolio.
Approximately 75% of the issuance size has been earmarked for qualified institutional buyers (QIBs), 15% for non-institutional investors, and the remaining 10% for retail investors.
The public offering, with a price range of Rs 265-274 per share, will end on December 20. Investors can bid a minimum of 54 equity shares and in multiples of they.
Supriya Lifescience has raised Rs 315 crore from anchor investors. BNP Paribas Arbitrage, Societe Generale, Reliance General Insurance Company, Aditya Birla Sun Life Insurance Company, Kuber India Fund, Saint Capital Fund and Nippon India Mutual Fund are among the fixed investors.
The IPO consists of an issue of new shares worth Rs 200 crore and an offer to sell (OFS) up to 500 crore by its promoter Satish Waman Wagh.
Currently, the promoter holds 99.26% of the company’s shares, and the promoter team owns 0.72%.
Proceeds from the new issue will be used to fund capital expenditure requirements, repay debt, and for general corporate purposes.
Supriya Lifescience is one of India’s major manufacturers and suppliers of active pharmaceutical ingredients (APIs), with a focus on research and development.
ICICI Securities and Axis Capital is the leading executive book on public affairs.
https://www.ndtv.com/business/supriya-lifescience-ipo-subscribed-2-33-times-on-first-day-of-issue-2655101 Supriya Lifescience IPO registered 2.33 times on the first day of release